<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="" /><meta name="keywords" content="Beclometasone dipropionate: asthma; Budesonide: asthma; Fluticasone propionate: asthma; Mometasone: asthma; Symbicort; Fostair; Chlorofluorocarbon propellants; CFC see Chlorofluorocarbon propellants; Hydrofluoroalkane propellants; HFA see Hydrofluoroalkane propellants" /><meta name="IX" content="Beclometasone dipropionate: asthma; Budesonide: asthma; Fluticasone propionate: asthma; Mometasone: asthma; Symbicort; Fostair; Chlorofluorocarbon propellants; Hydrofluoroalkane propellants" /><meta name="IXN" content="CFC see Chlorofluorocarbon propellants; HFA see Hydrofluoroalkane propellants" /><title>3.2 Corticosteroids: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../383/theme.css" /><link type="text/css" rel="stylesheet" href="204/style.css" /><link type="image/x-icon" rel="shortcut icon" href="../../favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP1843-corticosteroids.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.8/jquery.min.js"></script><script type="text/javascript" src="../../383/scripts.js"></script><style type="text/css">
          .contentsbox { position: fixed; z-index:1001; }
          .contentsbox_wrap { overflow: hidden; width: 20px; height: 130px; position: absolute; left: 0; top: 0; }
        </style><!--[if IE 8]>
          <style type="text/css">
          #p1 {
          float: left;
          padding-bottom: 15em;
          }
          </style>
          <![endif]--><!--[if lte IE 8]>
          <style type="text/css">
          #start-search input {
          height: 28px;
          padding-top: 8px;
          }
          @media screen {
          #pV {
          display: block !important;
          }
          }
          </style>
          <![endif]--><!--[if IE 7]>
          <style type="text/css">
          #start-search input {
          position: absolute !important;
          left: 0;
          top: 0;
          }
          .as-shadow {
          margin-left: -4px !important;
          color: silver;
          }
          </style>
          <![endif]--><!--[if lte IE 7]>
          <style type="text/css">
          .menu {
          height: 1%;
          }
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }

          #account-info ul li a {
          width: 12em;
          }
          #opts ul li span {
          width: 12em;
          }
          div.as-select ul li ul li span {
          width: 40em;
          }
          div.menu ul li ul li {
          float: left !important;
          }
          #pQ fieldset, #qd, #input-box, #pub-list, #start-search, #end-search {
          display: inline;
          float: left;
          height: 100%;
          padding: 0;
          margin: 0;
          position: relative;
          }
          #hM a, #hM a img {
          border: none;
          display: inline-block;
          float: left;
          }
          #qd input {
          float: left;
          display: inline-block !important;
          }
          #start-search input {
          height: 28px;
          padding-top: 8px !important;
          }
          #end-search, #end-search input {
          height: 36px !important;
          }
          #hM, #content, #searchForm, #purple-menu {
          width: expression(document.body.clientWidth > 63 * parseInt(document.body.currentStyle.fontSize) ? '63em': 'auto');
          margin: 0 auto;
          }
          #pQ {
          z-index: 1;
          }
          </style>
          <![endif]--><!--[if lte IE 6]>
          <style type="text/css">
          body {
          height: 100%;
          }
          div.menu ul li a, div.menu ul li span {
          display: inline-block;
          }
          div.menu ul li ul li {
          clear: both;
          }
          div.as-select ul li span {
          height: 20px;
          padding-top: 16px;
          padding-left: 1em;
          padding-bottom: 0;
          padding-left: 1em;
          margin: 4px 0;
          border-right: 1px solid #888;
          background-image: url("images/dropdown_img.png");
          background-repeat: repeat-x;
          overflow-x: hidden;
          }
          div.as-select ul li ul li span {
          font: bold 10px Verdana !important;
          padding: 4px 1em !important;
          color: #2D2D2D;
          background: white;
          text-decoration: none !important;
          white-space: nowrap;
          border: none !important;
          float: left;
          }
          div.menu span.hover {
          background: #8F1F8D;
          color: white;
          }
          </style>
          <![endif]--></head><body><!--[if lte IE 6]>
          <script type="text/javascript">
          jQuery(document).ready(function($) {
          $('a.mclogo').html('<img src="images/mc_logo.gif" class="logo" />');
          });
          </script>
          <![endif]--><?highlighter off?><div id="hC"><div id="vH"><div id="pU"><a class="mclogo" href="http://www.medicinescomplete.com/about/"><img class="logo" src="../../images/mc_logo.png" alt="MedicinesComplete" /></a><div id="hM"><div id="vM" class="menu"><ul><li><a href="http://www.medicinescomplete.com/mc/index.htm">Home</a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm">Help</a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP1843-corticosteroids.htm">Feedback</a></li><li id="account-info"><a href="http://www.medicinescomplete.com/mc/account.htm">BNF.org Free Access</a><ul><li><a href="http://www.medicinescomplete.com/mc/account.htm">My Account</a></li><li><a href="http://www.medicinescomplete.com/mc/subscribe.htm">Subscribe</a></li><li><a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li><a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul></li></ul></div><a id="pD" accesskey="s" rel="bookmark" href="PHP1843-corticosteroids.htm#pB" title="Skip Navigation">Skip Navigation</a></div></div><div id="pA"><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 12 Mar 2013 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="search-in">Publication</label><label for="q">Search for</label><div id="qd"><div id="start-search"><div class="as-select menu" id="pub-list"><ul><li><span>British National Formulary</span><ul></ul></li></ul></div><div id="input-box"><input type="text" id="q" name="q" accesskey="4" /></div></div><div id="end-search"><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div></div></div><div id="pH"><div id="pN"><div id="pT"><!--[if lte IE 7]>
             
            <![endif]--><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF March 2013</a> &gt; <a href="PHP1716-respiratory-system.htm">3 Respiratory system</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP1841-nebuliser-diluent.htm" title="Previous: Nebuliser diluent">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP1849-beclometasone-dipropionate.htm" title="Next: BECLOMETASONE DIPROPIONATE">Next page</a> ►</div></div></div></div><div id="content"><div id="p1"><div id="pB"><?highlighter on?><h1><span>3.2 </span>Corticosteroids</h1><?highlighter off?><?highlighter on?><div id="pC" class="jN"><div class="cL"><div class="cE"><h3 class="cO">Additional information</h3> <p class="cT"> interactions (<a href="bnf_int484-corticosteroids.htm">Corticosteroids</a>).</p></div></div><p>Corticosteroids are used for the management of reversible and irreversible airways disease. An inhaled corticosteroid used for 3–4 weeks may help to distinguish asthma from chronic obstructive pulmonary disease; clear improvement over 3–4 weeks suggests asthma. </p><div id="PHP1844"><h2>Asthma</h2><p>Corticosteroids are effective in <em>asthma</em>; they reduce airway inflammation (and hence reduce oedema and secretion of mucus into the airway).</p><p>An inhaled corticosteroid is used regularly for prophylaxis of asthma when patients require a beta<sub>2</sub> agonist more than twice a week, or if symptoms disturb sleep at least once a week, or if the patient has suffered an exacerbation in the last 2 years requiring a systemic corticosteroid (see <a title="topic: MANAGEMENT OF CHRONIC ASTHMA IN ADULTS AND CHILDREN" href="PHP1728-management-of-chronic-asthma.htm">Management of Chronic Asthma table</a>). <em>Regular use</em> of inhaled corticosteroids reduces the risk of exacerbation of asthma.</p><p>Current and previous smoking reduces the effectiveness of inhaled corticosteroids and higher doses may be necessary.</p><p>Corticosteroid inhalers must be used regularly for maximum benefit; alleviation of symptoms usually occurs 3 to 7 days after initiation. <strong>Beclometasone dipropionate</strong>, <strong>budesonide</strong>, <strong>fluticasone propionate</strong>, and <strong>mometasone furoate</strong> appear to be equally effective. Preparations that combine a corticosteroid with a long-acting beta<sub>2</sub> agonist may be helpful for patients stabilised on the individual components in the same proportion.</p><p>In adults using an inhaled corticosteroid and a long-acting beta<sub>2</sub> agonist for the prophylaxis of asthma, but who are poorly controlled, (see step 3 of the <a title="topic: Management of chronic asthma in adults and children" href="PHP1728-management-of-chronic-asthma.htm">Management of Chronic Asthma table</a>) <em>Symbicort</em>® (budesonide with formoterol) can be used as a reliever (instead of a short-acting beta<sub>2</sub> agonist), in addition to its regular use for the prophylaxis of asthma. <em>Symbicort</em>® can also be used in this way in adults using an inhaled corticosteroid with a dose greater than beclometasone dipropionate 400 micrograms daily<cite><a href="PHP1843-corticosteroids.htm#ID0ESDFBA" class="tooltip ID0ESDFBA">(1)</a></cite>, but who are poorly controlled (see step 2 of the <a title="BNF:topic: Management of chronic asthma" href="PHP1728-management-of-chronic-asthma.htm">Management of Chronic Asthma table</a>). When starting this treatment, the total regular daily dose of inhaled corticosteroid should not be reduced. Patients must be carefully instructed on the appropriate dose and management of exacerbations before initiating this therapy, see <em><a title="Symbicort®" href="PHP1864-symbicort.htm#PHP1864-symbicort">Symbicort</a></em>®. Patients using budesonide with formoterol as a reliever once a day or more should have their treatment reviewed regularly. The use of <em>Symbicort® </em>for both reliever and maintenance therapy is also used by some specialists in children 12–18 years [unlicensed]. <em>Fostair® </em>can also be used in adults as a reliever (instead of a short-acting beta<sub>2</sub> agonist) in addition to its regular use for the prophylaxis of asthma, see <a title="Fostair®" href="PHP1856-fostair.htm#PHP1856-fostair"><em>Fostair</em>®</a>. It may be particularly useful for patients with poorly controlled asthma requiring reliever therapy, or for those who have had previous exacerbations of asthma which needed medical intervention. Patients requiring frequent daily use of <em>Fostair®</em> as a reliever should have their maintenance treatment reviewed. This approach has not been investigated with combination inhalers containing other corticosteroids and long-acting beta<sub>2</sub> agonists.</p>  <p>High doses of inhaled corticosteroid can be prescribed for patients who respond only partially to standard doses with a long-acting beta<sub>2</sub> agonist or another long-acting bronchodilator (see <a title="topic: MANAGEMENT OF CHRONIC ASTHMA IN ADULTS AND CHILDREN" href="PHP1728-management-of-chronic-asthma.htm">Management of Chronic Asthma table</a>). High doses should be continued only if there is clear benefit over the lower dose. The recommended maximum dose of an inhaled corticosteroid should not generally be exceeded. However, if a higher dose is required, then it should be initiated and supervised by a specialist. The use of high doses of inhaled corticosteroid can minimise the requirement for an oral corticosteroid.</p><p>Systemic corticosteroid therapy may be necessary during episodes of stress, such as severe infection, or if the asthma is worsening, when higher doses are needed and access of inhaled drug to small airways may be reduced; patients may need a reserve supply of corticosteroid tablets.</p></div><div><h2>Chronic obstructive pulmonary disease</h2><p>In <em>chronic obstructive pulmonary disease</em> inhaled corticosteroid therapy may reduce exacerbations when given in combination with an inhaled long-acting beta<sub>2</sub> agonist, see <a title="BNF:topic: Chronic obstructive pulmonary disease" href="PHP1724-chronic-obstructive-pulmonary-disease.htm">section 3.1</a>.</p></div><div id="PHP1845"><h2>Cautions of inhaled corticosteroids</h2><div><div class="cE"><h3 class="cT">Paradoxical bronchospasm</h3> <p class="cT">The potential for paradoxical bronchospasm (calling for discontinuation and alternative therapy) should be borne in mind—mild bronchospasm may be prevented by inhalation of a short-acting beta<sub>2</sub> agonist beforehand (or by transfer from an aerosol inhalation to a dry powder inhalation).</p></div></div><div><div class="cE"><h3 class="cT">CFC-free inhalers</h3> <p class="cT">Chlorofluorocarbon (CFC) propellants in pressurised aerosol inhalers have been replaced by hydrofluoroalkane (HFA) propellants.</p></div></div><p>Doses for corticosteroid CFC-free pressurised metered-dose inhalers may be different from traditional CFC-containing inhalers and may differ between brands, see MHRA/CHM advice below. </p><p>For <strong>interactions:</strong> see Appendix 1 (corticosteroids)</p> <div class="cI" id="PHP1847"><h3>MHRA/CHM advice (July 2008)</h3><ul><li><p>Beclometasone dipropionate CFC-free pressurised metered-dose inhalers (<em>Qvar</em>® and <em>Clenil Modulite</em>®) are <strong>not</strong> interchangeable and should be prescribed by brand name; <em>Qvar</em>® has extra-fine particles, is more potent than traditional beclometasone dipropionate CFC-containing inhalers, and is approximately twice as potent as <em>Clenil Modulite</em>®;</p> </li><li><p><em>Fostair</em>® is a combination beclometasone dipropionate and formoterol fumarate CFC-free pressurised metered-dose inhaler; <em>Fostair</em>® has extra-fine particles and is more potent than traditional beclometasone dipropionate CFC-free inhalers.</p> </li></ul></div> </div><div id="PHP1848"><h2>Side-effects of inhaled corticosteroids</h2><p>Inhaled corticosteroids have considerably fewer systemic effects than oral corticosteroids (<a title="topic: Disadvantages of corticosteroids" href="PHP4353-side-effects-of-corticosteroids.htm">section 6.3.2</a>), but adverse effects have been reported.</p><p>High doses of inhaled corticosteroids (see <a title="topic: Management of chronic asthma in adults and children" href="PHP1728-management-of-chronic-asthma.htm">Management of Chronic Asthma table</a>) used for prolonged periods can induce adrenal suppression. Inhaled corticosteroids have been associated with adrenal crisis and coma in children; excessive doses should be <strong>avoided</strong>. Patients using high doses of inhaled corticosteroids should be given a ‘steroid card’ (<a title="topic: Steroid treatment card" href="PHP4355-steroid-treatment-card.htm">section 6.3.2</a>) and specific written advice to consider corticosteroid replacement during an episode of stress, such as severe intercurrent illness or an operation.</p><p>High doses of inhaled corticosteroid have been associated with lower respiratory tract infections, including pneumonia, in older patients with chronic obstructive pulmonary disease.</p><p>Bone mineral density may be reduced following long-term inhalation of higher doses of corticosteroids, predisposing patients to osteoporosis (<a title=" Drugs affecting bone metabolism" href="PHP4642-drugs-affecting-bone-metabolism.htm">section 6.6</a>). It is therefore sensible to ensure that the dose of an inhaled corticosteroid is no higher than necessary to keep a patient's asthma under good control.</p><p>In children, growth restriction associated with systemic corticosteroid therapy does not seem to occur with recommended doses of inhaled therapy; although initial growth velocity may be reduced, there appears to be no effect on achieving normal adult height. However, the height and weight of children receiving prolonged treatment with inhaled corticosteroid should be monitored annually; if growth is slowed, referral to a paediatrician should be considered. Large-volume spacer devices should be used for administering inhaled corticosteroids in children under 15 years (<a title="target-block: NICE for drug delivery devices" href="PHP1829-drug-delivery-devices.htm#PHP1830">see NICE guidance, section 3.1.5</a>); they are also useful in older children and adults, particularly if high doses are required. Spacer devices increase airway deposition and reduce oropharyngeal deposition.</p><p>A small risk of glaucoma with prolonged high doses of inhaled corticosteroids has been reported. Hoarseness, dysphonia, throat irritation, and candidiasis of the mouth or throat may occur with inhaled corticosteroids (see Candidiasis below). Paradoxical bronchospasm has been reported very rarely. Anxiety, depression, sleep disturbances, behavioural changes including hyperactivity, irritability, and aggression (particularly in children) have been reported; hyperglycaemia (usually only with high doses), cataracts, skin thinning and bruising have also been reported.</p><div><div class="cE"><h3 class="cT">Candidiasis</h3> <p class="cT">The risk of oral candidiasis can be reduced by using a spacer device with the corticosteroid inhaler; rinsing the mouth with water (or cleaning a child's teeth) after inhalation of a dose may also be helpful. Antifungal oral suspension or oral gel (<a title="sub-section: Oropharyngeal anti-infective drugs" href="PHP7380-oropharyngeal-anti-infective-drugs.htm">section 12.3.2</a>) can be used to treat oral candidiasis without discontinuing therapy.</p></div></div></div><div><h2>Oral</h2><p>An acute attack of asthma should be treated with a short course of an oral corticosteroid starting with a high dose, see <a title="BNF:topic: Management of acute asthma" href="PHP1729-management-of-acute-asthma.htm">Management of Acute Asthma table</a>. Patients whose asthma has deteriorated rapidly usually respond quickly to corticosteroids. The dose can usually be stopped abruptly; tapering is not needed provided that the patient receives an inhaled corticosteroid in an adequate dose (apart from those on maintenance oral corticosteroid treatment or where oral corticosteroids are required for 3 or more weeks); see also Withdrawal of Corticosteroids, <a title="BNF:sub-topic: Withdrawal of corticosteroids" href="PHP4341-withdrawal-of-corticosteroids.htm">section 6.3.2</a>. In patients who have needed several courses of oral corticosteroids and in whom the possibility of a period on maintenance corticosteroids is being considered, it may be useful to taper the corticosteroid dose gradually to identify a threshold dose for asthma control. This should only be done after other standard options for controlling asthma have been tried (see the <a title="BNF:topic: Management of chronic asthma" href="PHP1728-management-of-chronic-asthma.htm">Management of Chronic Asthma table</a>).</p><p>In chronic asthma, when the response to other drugs has been inadequate, longer term administration of an oral corticosteroid may be necessary; in such cases high doses of an inhaled corticosteroid should be continued to minimise oral corticosteroid requirements, see <a title="BNF:topic: Management of chronic asthma" href="PHP1728-management-of-chronic-asthma.htm">Management of Chronic Asthma table</a>. Patients taking long-term oral corticosteroids for asthma can often be transferred to an inhaled corticosteroid but the transfer must be slow, with gradual reduction in the dose of the oral corticosteroid, and at a time when the asthma is well controlled.</p><p> During an acute exacerbation of chronic obstructive pulmonary disease, prednisolone 30 mg daily should be given for 7–14 days; treatment can be stopped abruptly. Prolonged treatment with oral prednisolone is of no benefit and maintenance treatment is not normally recommended.</p><p>An oral corticosteroid should normally be taken as a single dose in the morning to reduce the disturbance to circadian cortisol secretion. Dosage should always be titrated to the lowest dose that controls symptoms. Regular peak-flow measurements help to optimise the dose.</p></div><div><h2>Parenteral</h2><p>For the use of hydrocortisone injection in the emergency treatment of acute severe asthma, see <a title="topic: MANAGEMENT OF ACUTE SEVERE ASTHMA IN GENERAL PRACTICE" href="PHP1729-management-of-acute-asthma.htm">Management of Acute Asthma table</a>.</p><div class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Inhaled corticosteroids for the treatment of chronic asthma (children under 12 years, November 2007; adults and children over 12 years, March 2008)</h3><p>For adults and children with chronic asthma in whom treatment with an inhaled corticosteroid is considered appropriate, the least costly product that is suitable for an individual (taking into consideration NICE TAs 38 and 10), within its marketing authorisation is recommended.</p>For adults and children with chronic asthma in whom treatment with an inhaled corticosteroid and a long-acting beta<sub>2</sub> agonist is considered appropriate, the following apply:<ul><li>the use of a combination inhaler within its marketing authorisation is recommended as an option;</li><li>the decision to use a combination inhaler or two agents in separate inhalers should be made on an individual basis, taking into consideration therapeutic need, and the likelihood of treatment adherence;</li><li>if a combination inhaler is chosen, then the least costly inhaler that is suitable for the individual is recommended.</li></ul><p><a href="http://www.nice.org.uk/TA131">www.nice.org.uk/TA131</a></p><p><a href="http://www.nice.org.uk/TA138">www.nice.org.uk/TA138</a></p></div></div></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP1849-beclometasone-dipropionate"><a href="PHP1849-beclometasone-dipropionate.htm" title="BECLOMETASONE DIPROPIONATE">BECLOMETASONE DIPROPIONATE</a></li><li id="_PHP1859-budesonide"><a href="PHP1859-budesonide.htm" title="BUDESONIDE">BUDESONIDE</a></li><li id="_PHP1867-ciclesonide"><a href="PHP1867-ciclesonide.htm" title="CICLESONIDE">CICLESONIDE</a></li><li id="_PHP1869-fluticasone-propionate"><a href="PHP1869-fluticasone-propionate.htm" title="FLUTICASONE PROPIONATE">FLUTICASONE PROPIONATE</a></li><li id="_PHP1875-mometasone-furoate"><a href="PHP1875-mometasone-furoate.htm" title="MOMETASONE FUROATE">MOMETASONE FUROATE</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP1841-nebuliser-diluent.htm">Previous: Nebuliser diluent</a> | <a class="top" href="PHP1843-corticosteroids.htm#">Top</a> | <a accesskey="]" href="PHP1849-beclometasone-dipropionate.htm">Next: BECLOMETASONE DIPROPIONATE</a> ►</div><ol class="cC"><li class="footnote" id="ID0ESDFBA"><p>For standard doses of other inhaled corticosteroids, see <a title="BNF:topic: Management of chronic asthma" href="PHP1728-management-of-chronic-asthma.htm">Management of Chronic Asthma table</a>.</p></li></ol></div></div></div><div id="pF"><div id="p2"><div id="pL"><div class="p4"><h2>Keep in touch</h2><ul><li><a href="http://www.pharmpress.com/?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Pharmaceutical Press</a></li><li><a href="http://www.rpharms.com/">Royal Pharmaceutical Society</a></li><li><a href="http://www.pharmpress.com/mc-alerts.asp?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Sign up for our eNewsletter</a></li><li><a href="http://twitter.com/#!/PharmPress/" class="p5"><img src="../../images/twitter.png" alt="Twitter logo" />Follow us on Twitter
              </a></li><li><a href="http://www.facebook.com/pages/Pharmaceutical-Press/296104187066918" class="p5"><img src="../../images/facebook.png" alt="Facebook logo" />Find us on Facebook
              </a></li></ul></div><div class="p4"><h2>Help and Support</h2><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a></li><li><a href="http://www.medicinescomplete.com/about/contact.htm">Contact Us</a></li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a></li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a></li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div><div class="p4"><h2>Provided for</h2><div id="cL"><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2013.  All rights reserved.</a></p><p><a href="http://www.medicinescomplete.com/mc/copyright.htm">MedicinesComplete © The Pharmaceutical Press 2013</a></p></div></div></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>